Northwest Biotherapeutics Narrows Q1 Net Loss to $3.4M, Revenue Up 31.7%
NWBO sits 33% above its 52-week low of $0.19.
Summary
Northwest Biotherapeutics reported first-quarter 2026 revenue of $494K, a 31.7% increase year-over-year, and significantly narrowed its net loss to ($3.4M) from ($19.61M) in the prior-year quarter, an 82.7% improvement. Diluted EPS was $0, up from ($0.01). This positive financial update follows the company's recent 10-K filing, which included a 'going concern' warning and highlighted substantial net losses. The substantial reduction in net loss and revenue growth are material developments for a company facing financial health concerns, potentially signaling improved operational efficiency or cost management. Traders will be watching for continued progress in the UK MAA review for DCVax-L and the US manufacturing scale-up, as well as the anticipated FDA submission for the in-licensed Kalinski program in Q2, which are critical for long-term viability and revenue generation.
At the time of this announcement, NWBO was trading at $0.25 on OTC in the Life Sciences sector, with a market capitalization of approximately $405.7M. The 52-week trading range was $0.19 to $0.37. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.